{{Rsnum
|rsid=34489327
|geno1=(-;-)
|geno2=(-;TTAAAG)
|geno3=(TTAAAG;TTAAAG)
|Orientation=plus
|Chromosome=18
|position=673451
|Gene=TYMS
|Assembly=GRCh37.p10
|GenomeBuild=37.5
|dbSNPBuild=138
|Gene_s=ENOSF1,TYMS
|Status=Deleted
}}{{PharmGKB
|RSID=rs34489327
|Name_s=TYMS:1494del, 6-basepair 3'UTR repeat (ttaaag)
|Gene_s=TYMS, ENOSF1
|Feature=
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the TYMS:1494del, 6-basepair 3&apos;UTR repeat variant (ttaaag), the 6-bp deletion was at frequency was 0.27 and 0.56 in Europeans and Africans, respectively. There was a significant difference between ethnic groups in genotype frequency distribution (p < 0.001). Study size: 252. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 60) and African (n = 89) descent. Significance metric(s): p < 0.001. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110726
}}

{{PharmGKB
|RSID=rs34489327
|Name_s=TYMS:-TTAAAG
|Gene_s=TYMS, ENOSF1
|Feature=
|Evidence=PubMed ID:15115918
|Annotation=6bp deletion in the 3'UTR, associated with decreased mRNA stability and lower TYMS expression.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145123
}}

{{PharmGKB
|RSID=rs34489327
|Name_s=TYMS:1494del TTAAAG
|Gene_s=TYMS, ENOSF1
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/tyms/variant.jsp
|Annotation=This SNP is a 6bp deletion 447bp downstream of the TYMS transcription stop codon. Data suggests that this deletion alters TYMS mRNA stability.
|Drugs=fluorouracil; methotrexate
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161845842
}}

{{PMID Auto
|PMID=22825513
|Title=Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer
}}

{{PMID Auto
|PMID=24554028
|Title=Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
}}

{{PMID Auto
|PMID=25227144
|Title=Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome
}}
{{on chip | 23andMe v3}}